Journal: Oncology Letters

Article Title: LATS2 expression differences in lung adenocarcinoma and lung squamous cell carcinoma analyzed using bioinformatics and experimental approaches

doi: 10.3892/ol.2026.15671

Figure Lengend Snippet: Comprehensive expression analysis of LATS2 in LUAD and LUSC. (A) Expression levels of LATS2 in LUAD and LUSC analyzed using the Gene Set Cancer Analysis platform. (B) Comparative analysis of LATS2 expression between tumor and normal tissues in LUAD using independent sample t-test and paired sample t-test. (C) Comparative analysis of LATS2 expression between tumor and normal tissues in LUSC using independent sample t-test and paired sample t-test. (D) Differential expression of LATS2 between LUAD and LUSC tumor tissues. (E) Immunohistochemical validation of LATS2 expression in LUAD, LUSC and normal lung tissues using the Human Protein Atlas database (antibody ID: 039191). All the data are presented as mean ± SD. ***P<0.001. LATS2, large tumor suppressor kinase 2; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; TPM, transcripts per million; RSEM, RNA-seq by expectation-maximization.

Article Snippet: Immunohistochemical images obtained from the Human Protein Atlas database indicated that the proportion of LATS2-positive cells was markedly higher in normal lung tissues compared with LUAD and LUSC tumor tissues ( ).

Techniques: Expressing, Quantitative Proteomics, Immunohistochemical staining, Biomarker Discovery, RNA Sequencing

Journal: iScience

Article Title: ExIR enables prioritizing driver and biomarker genes from omics data in a reference free manner

doi: 10.1016/j.isci.2026.116303

Figure Lengend Snippet: Differential immunoreactivity of known and novel ExIR-predicted LUAD biomarkers between normal and cancer samples (A–E) Immunohistochemical (IHC) data from the Human Protein Atlas database in LUAD and normal lung tissue for top five known LUAD biomarkers. (A) SFTPC–ExIR rank #1, LUAD (negative intensity; patient ID: 1847) and normal pneumocytes (quantity: 75%–25%; strong intensity; patient ID: 2268). (B) SPP1—ExIR rank #117, LUAD (quantity: >75%; moderate intensity; patient ID: 537) and normal pneumocytes (not detected; patient ID: 2268). (C) CBLC—ExIR rank #140, LUAD (quantity: >75%; moderate intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2417). (D) MDK—ExIR rank #247, LUAD (quantity: 75%–25%; strong intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2222). (E) MRC1 – ExIR rank #471, LUAD (undetected; patient ID: 1932) and normal macrophages (quantity: 75%–25%; strong intensity; patient ID: 2208). (F–I) IHC data of top five ExIR-predicted LUAD biomarkers (excluding SFTPC rank #1 already in a). (F) AGER – ExIR rank #2, LUAD (not detected; patient ID: 3144) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 4840). (G) EMP2 – ExIR rank #3, LUAD (not detected; patient ID: 1847) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 2101). (H) CAV1 – ExIR rank #4, LUAD (not detected; patient ID: 1249) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 2208). i, RTKN2 – ExIR rank 5, LUAD (not detected; patient ID: 3003) and normal pneumocytes (quantity: <25%; moderate intensity; patient ID: 2268).(J–N) IHC data of top six ExIR-predicted LUAD up-regulated biomarkers (excluding FAM83A rank #2, for which no IHC data was available). (J) PYCR1 – ExIR rank #1, LUAD (quantity: >75%; moderate intensity; patient ID: 2777) and normal pneumocytes (not detected; patient ID: 2208). (K) TOP2A – ExIR rank #3, LUAD (quantity: 75%–25%; strong intensity; patient ID: 3003) and normal pneumocytes (quantity: 75%–25%; weak intensity; patient ID: 2101). (L) MMP11 – ExIR rank #4, LUAD (quantity: >75%; weak intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2438). (M) TEDC2– ExIR rank 5, LUAD (quantity: 75%–25%; moderate intensity; patient ID: 4208) and normal pneumocytes (not detected; patient ID: 1470). (N) IQGAP3– ExIR rank 6, LUAD (quantity: >75%; strong intensity; patient ID: 3048) and normal pneumocytes (not detected; patient ID: 1470). Per the Human Protein Atlas database usage guidelines, the link to the immunostaining images of all of the selected proteins in normal pneumocytes and LUAD samples are included as hyperlinks within the figure legend. Ab: antibody; LUAD: lung adenocarcinoma.

Article Snippet: Per the Human Protein Atlas database usage guidelines, the link to the immunostaining images of all of the selected proteins in normal pneumocytes and LUAD samples are included as hyperlinks within the figure legend.

Techniques: Immunohistochemical staining, Immunostaining

Journal: International Journal of Nanomedicine

Article Title: Transferrin-Functionalized Conjugated Polymer Nanoparticles for Enhanced Photodynamic Therapy of Glioblastoma

doi: 10.2147/IJN.S592688

Figure Lengend Snippet: Integrated in silico and experimental analysis of transferrin receptor 1 (TfR1 / TFRC) expression in gliomas and representative cell lines. Box-plot summary of TFRC mRNA expression obtained from GEPIA (Gene Expression Profiling Interactive Analysis) based on tumor and normal samples from the TCGA and the GTEx databases (accessed March 2025). ( A ) Comparison of TFRC expression in high-grade gliomas (GBM) vs. low-grade glioma (LGG) (n indicated on each plot). ( B ) TFRC expression stratified by canonical GBM molecular subtype (classical, mesenchymal, neural, proneural). Boxes represent the interquartile range, horizontal lines the median, whiskers extend to 1.5×IQR, and individual data points are overlaid. Brackets with asterisks denote statistically significant pairwise differences (see Methods for statistical test). ( C ) TfR1 expression levels in GBM cell lines and HEK293 (non-tumor control). Data taken and adapted from the Human Protein Atlas. ( D ) Representative flow-cytometry histograms of surface TfR1 staining in U87MG, T98G, MO59K and HEK293 cells. Traces correspond to unstained control (red), secondary-only control (anti-mouse IgG–AF647; Orange) and specific anti-CD71 primary staining followed by anti-mouse-AF647 secondary (blue). The horizontal bracket on each histogram indicates the gate used to define TfR1-positive events. ( E ) gMFI of the CD71 signal (mean ± SD; n = biological replicates indicated in Methods), and ( F ) percentage of TfR1-positive cells. Data were normalized to appropriate controls. Statistical comparisons were performed as described in Methods (* p < 0.05 ).

Article Snippet: In addition, representative immunohistochemistry (IHC) images illustrating TfR1 protein expression in human brain tissues were retrieved from the Human Protein Atlas (HPA) database ( https://www.proteinatlas.org ), an open-access resource providing antibody-based protein expression profiles across normal and cancer tissues.

Techniques: In Silico, Expressing, Gene Expression, Comparison, Control, Flow Cytometry, Staining